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ABSTRACT 
 
Cancer cells are susceptible to oncolytic viruses, albeit variably. Human 
adenoviruses (HAdVs) are widely used oncolytic agents, engineered to produce 
progeny within the tumor, and elicit bystander effects. We searched for host factors 
enhancing bystander effects, and conducted a targeted RNA-interference screen 
against guanine-nucleotide exchange factors (GEFs) of small GTPases. We show 
that unfolded protein response (UPR), which is readily inducible in aggressive tumor 
cells, enhances melanoma or epithelial cancer cell killing upon HAdV infection. UPR 
was triggered by knock-down of Golgi Brefeldin-A resistant guanine-nucleotide-
exchange factor-1 (GBF-1), or the GBF-1 inhibitor Golgicide A (GCA), and 
stimulated HAdV infection. GBF-1 is a GEF for ADP-ribosylation factors (Arfs) 
regulating ER to Golgi and intra-Golgi transport. Cells treated with GCA enhanced 
HAdV-induced cytopathic effects in epithelial and melanoma cancer but not normal 
cells, if the drug was applied several hours prior to HAdV inoculation. This was 
shown by real-time label-free impedance measurements using xCELLigence™. 
GCA-treated cells contained fewer incoming HAdV than control cells, but boosted 
HAdV titers and spreading in cancer cells. GCA enhanced viral gene expression, or 
transgene expression from the cytomegalovirus promoter of B- or C-species HAdVs, 
but did not enhance viral E1A expression in uninfected cell lines, or cells transfected 
with plasmid reporter DNA. The UPR-enhanced cell killing required the nuclease 
activity of the UPR-sensor inositol-requiring enzyme 1 (IRE-1), and X-box binding 
protein 1 (XBP-1), which alleviate ER stress. The collective results show that 
chemical UPR induction and viruses boost tumor cell killing by enhancing oncolytic 
viral efficacy. 
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IMPORTANCE 
 
Cancer is difficult to combat. A wide range of oncolytic viruses show promise for 
killing cancer cells. Yet, the efficacy of oncolytic killing is low. We searched for host 
factors enhancing adenovirus cancer cell killing, and found that the knock-down of 
GBF-1 (Golgi Brefeldin-A resistant guanine-nucleotide-exchange factor-1) or 
chemical inhibition of GBF-1 enhanced adenovirus infection by triggering the IRE- 
1/XBP-1 branch of the unfolded protein response (UPR). IRE-1/XBP-1 promote cell 
survival, and enhanced the levels of the adenoviral immediate early gene product 
E1A, virus spreading, and killing of cancer cells. Aggressive tumor cells depend on a 
readily inducible UPR, and hence present prime targets for a combined strategy 
involving adenoviruses and small chemicals inducing UPR. 
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INTRODUCTION 
Cancer is a devastating multifactorial disease, and difficult to combat owing to 
genomic instability, uncontrolled proliferation, dissemination, and poor immunologic 
control (for reviews, see 8, 25). Oncolytic viruses are an emerging therapeutic 
practice (reviewed in 1, 53). Oncolytic viral therapy takes advantage of the fact that 
many enveloped and non-enveloped viruses destroy host cells as parts of their 
replication strategy. Oncolytic viruses include herpes virus, measles virus, vesicular 
stomatitis virus, influenza A virus, Newcastle disease virus, vaccinia virus, 
poliovirus, parvovirus and adenovirus. Currently, human adenoviruses (HAdVs) are 
the most widely used oncolytic agents, engineered to produce progeny within the 
tumor, and kill tumor rather than normal cells (20).  
Oncolytic viruses directly kill cancer cells, and may trigger an immune response 
against cancer specific or viral epitopes presented on major histocompatibility class 
1 protein to immune cells. This poses the problem that an oncolytic virus can be 
eliminated by the immune system before reaching full efficacy, for example, if the 
host is not tolerant against immune-dominant viral antigens. Since immune-
tolerance against dominant viral antigens is rare, other ways are explored to 
enhance the oncolytic efficacy of viruses. For example, treatments with biological 
agents, chemicals or physical induction of stress sensitize tumor cells to be killed by 
oncolytic viruses (3, 67). In some instances, stress induction leads to inhibition of 
virus replication, for example radiation therapy attenuates vaccinia virus infection 
(35). Alternatively, inhibition of cell stress can enhance oncolysis, for example 
blockage of ER stress augments rhabdovirus oncolysis (40).  
Here, we report that chemical or genetic inhibition of GBF-1 (Golgi Brefeldin-A 
resistant guanine-nucleotide-exchange factor-1) activates unfolded protein response 
(UPR) from the ER, and enhances gene expression from adenoviruses HAdV-C5 
and B3. GBF-1 inhibition boosts HAdV-induced cell killing, and viral dissemination in 
human lung epithelial or melanoma-derived cancer cells. GBF-1 is a cis-Golgi 
guanine nucleotide exchange factor (GEF) for ADP ribosylation factors (ARFs), and 
regulates ER-Golgi and intra-Golgi membrane traffic (12, 74). It is widely expressed 
in human cells, and controls the dynamics of ARF and COP-I at ER-Golgi interface 
(41, 63). Notably, GBF-1 depletion by RNAi induces the UPR by locating site 
specific protease (SP) 1 and 2 from Golgi to ER, and proteolytic activation of 
activating transcription factor 6 (ATF-6) (11).  
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HAdVs are wide-spread non-enveloped DNA viruses causing mild, self-limiting 
infections in immune-competent individuals (21). Species B and C HAdVs target the 
urogenital and respiratory tracts, and have been extensively developed into vectors 
for clinical therapy (20). They attach to host cells via the coxsackievirus adenovirus 
receptor (CAR), CD46 or desmoglein-2 and in most cases integrin secondary 
receptors (71). This triggers initial steps of virus uncoating, internalization and 
endosomal membrane rupture by pH-independent mechanisms (5, 46, 61). 
Cytosolic viruses are transported by dynein/dynactin and microtubules to the nuclear 
pore complex, where kinesin-mediated virus disassembly and disruption of the 
nuclear pore complex occur, and viral DNA is imported into the nucleus (4, 60, 62, 
70). Expression of the early region 1A (E1A) genes from episomal viral DNA 
controls a range of host and viral genes (14, 48). E1A starts the viral gene 
expression and genome replication programs, which drive viral immune escape and, 
ultimately, the release of progeny viruses from the nucleus upon cell lysis (66). Yet, 
the clinical oncolytic efficacy of adenoviruses and other virus-derived oncolytic 
vectors has been modest (44, 65). This is paralleled by a recent observation from 2-
dimensional cell cultures showing that inefficient viral transmission correlates with 
low events of lytic infection (72). The results here show that induction of UPR 
through the IRE-1 sensor and the XBP-1 transcription factor leads to enhanced viral 
cytotoxicity in primary human cancer cells. This is a hereto unknown pathway 
leading from ER stress and host transcriptional response to enhanced viral gene 
expression and oncolysis.  
 
MATERIALS AND METHODS 
 
Cells and viruses 
Cells and viruses were grown as described before (5, 19, 39, 47). A549 cells 
(American Type Culture Collection) are human lung epithelial carcinoma cells, 
HeLa-ATCC is a HeLa clone obtained from American Type Culture Collection, 911 
cells are human embryonic retinoblasts containing the base pairs 79-5789 of HAdV-
C5 genome (16), 293T cells are human embryonic kidney cells containing the base 
pairs 1-4344 of HAdV-C5 genome (15, 38), and WI38 is a human diploid cell line 
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derived from normal embryonic lung tissue (American Type Culture Collection). 
XBP-1 -/- and wildtype control mouse embryonal fibroblasts (MEFs, obtained from 
Laurie Glimcher, Weill Cornell Medical College) were maintained as described (36). 
The replicating HAdV-C5_wt and HAdV-C2-dE3B_GFP were grown in A549 cells as 
described (22, 23, 47). Non-replicating HAdV-C5-dE1_GFP (19, 47) and HAdV-B3-
dE1_GFP (57) containing GFP under the control of the CMV major immediate early 
promoter were grown in 911 cells. The formation of HAdV-C2-dE3B_GFP progeny 
was as described (49, 72). Cell viability was measured by resazurin as described 
(33). Infectious titer of HAdV-C5_wt and HAdV-C2-dE3B_GFP was determined on 
A549 cells, and that of HAdV-C5-dE1_GFP on 911 cells. 
Transfections and infections 
Knockdown experiments were performed in 96-well imaging plates (Greiner Bio-
one) using reverse transfection: siRNA (1 pmol/well diluted in 5 µl ddH2O, 
Dharmacon Smart Pool: ON-TARGET Plus) or siPools (siTools Biotech GmbH, 
Martinsried, Germany, 26) were mixed with Lipofectamine RNAiMAX (0.2 µl/well, 
Invitrogen) in 19.8 µl Optimem (Invitrogen), incubated at room temperature for 5 
min, and 6,000 A549 cells/well were added in 75 µl of growth medium. The medium 
was changed next day to fresh growth medium and 48h post transfection, cells were 
infected with HAdV-C5_wt [multiplicity of infection (MOI) 0.09] or HAdV-C5-
dE1_GFP (MOI 0.07) for 18 h, fixed and stained with 4′,6-diamidin-2-phenylindol 
(DAPI), or, in the case of HAdV-C5-wt infection, immunostained with rabbit anti-
protein VI antibody (5) and secondary AlexaFluor488-conjugated anti-rabbit 
antibody (Life Technologies). DAPI stain was used to mark the cell nucleus, and a 
custom made script (Matlab, Mathworks, USA) or a custom made CellProfiler 2.0 
pipeline (according to 7) were used to quantify the average nuclear intensity of the 
GFP and protein VI signals, which were used as measures of infection efficiency. 
The spreading of HAdV-C2-dE3B_GFP was analyzed by time lapse fluorescence 
microscopy as described (72). A detailed description of the imaging procedures is 
available on request. Human rhinovirus species A type A1 (HRV-A1A) infections 
were analyzed 7 h pi as described (34). 
In Golgicide A (GCA, Sigma) experiments, the cells were pretreated with the drug or 
its solvent DMSO for 5 h. GCA concentration in all experiments was 20 µM. To 
determine virus progeny formation from control vs GCA-treated cells, HAdV-C2-
dE3B_GFP (0.008 infectious units/cell) was added to confluent A549 cells and 
7 	  
progeny collected from the clarified culture medium, and from cells by Freon 
extraction 40 h post infection (pi). Samples were titrated on HeLa-ATCC cells grown 
on 96-well imaging plates using serial 10-fold dilutions of cell extracts or culture 
supernatants, at 18 h post infection samples were fixed, DAPI-stained and GFP 
positive cells were counted from wells that had lower than 100% infection. One GFP 
positive cell was scored as one infectious particle. 
 
Cell impedance measurements by xCELLigenceTM and cell counting 
The xCELLigenceTM system (Roche Applied Science and ACEA Biosciences) 
consists of four components, analyzer, device station, control unit with software and 
E-plates (disposable E-Plate 16). The device was used as described by the supplier 
(59). E-plates have a gold plated sensor array at the bottom, which measures 
electrical impedance across the plate. Impedance is recorded in terms of a 
dimensionless quantity termed cell index (CI). For background measurements, 100 
µl of culture medium was added to the E-plate well, equilibrated at 37˚C and 
supplemented with 6,500 or 25,000 cells at 37˚C. Forty-eight hours later, inhibitor 
was added to the cells for 5 h, followed by the addition of virus. Impedance was 
recorded every 15 minutes until the CI value reached background levels. 
Regression analyses and graphs were rendered in GraphPad Prism (GraphPad 
Software Inc.). To quantify the cytopathogenicity of HAdV infection, CI values were 
plotted against time and ∆CIT50, i.e. the time point when the CI of infected cells had 
decreased to 50% of maximum CI of non-infected cells, was determined. 
Differential interference contrast (DIC) images of A549 cells seeded on 96-well 
optical plates were obtained with a bright field microscope equipped with an 
AxioCam MRc5 camera (Carl Zeiss). For segmentation, images were enhanced 
using the band-pass filter and contrast enhanced in Image J. Manual counting of 
cells was performed using Image J built-in plugin cell counter.  
 
Immunoblot assays 
A549 cells grown in a 24-well plate were infected with HAdV-C5_wt (2 µg / sample) 
at 37˚C for 5 or 9 h, cell extracts prepared in hot SDS-PAGE sample buffer, boiled, 
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sheared through a 20-G needle and analyzed on 15% polyacrylamide gel. Proteins 
were transferred to PVDF membrane by semi-dry blotting (Hoefer TE 77, Amersham 
Biosciences). The membrane was blocked in 5% milk powder and incubated with 
M73 anti-E1A (Millipore, #05-599), anti-GBF-1 (BD Biosciences, #612116), anti-IRE-
1 (Cell Signaling Technology, #3294), anti-XBP-1 (Santa Cruz, #7160), anti-protein 
VI (5) or anti-β-tubulin antibodies (Amersham), washed with Tris-buffered saline with 
0.1% Tween 20 and incubated with horseradish peroxidase (HRP)-coupled 
secondary antibody (Cell Signaling Technology) followed by chemi-luminescence 
development using Amersham Hyperfilm ECL kit (GE Healthcare).  
 
XBP-1 splicing  
cDNA was synthesized from total RNA extracts and RT-PCR carried out with 
primers spanning XBP-1 as described (42). PCR products were restriction digested 
with PstI and analyzed by 2% agarose gel electrophoresis. 
 
GCA effects on gene expression from transfected or integrated DNA 
293T cells were treated with GCA for 5 h, and E1A levels were scored from cell 
extracts by immunoblotting with M73 anti-E1A antibody. pMAX-EGFP plasmid DNA 
(Amaxa) driving GFP expression from the CMV promoter was transfected into A549 
cells using Neon transfection (Life Technologies). After 24 h, transfected cells were 
treated with GCA for 5 h, washed, stained with Hoechst 33342, live imaged by 
automated high-throughput microscopy 5 or 21 h after drug washout, and single 
cells were analyzed for GFP expression by CellProfiler using a nuclear DAPI mask 
extended by 5-pixels to account for cytoplasmic GFP.  
 
Effect of GCA on HAdV-C5 binding to cells 
Cells grown on Alcian blue-coated coverslips were treated with GCA (20 µM) for 12 
or 0.5 h followed by inoculation with atto 565-labelled HAdV-C5_wt at cold for 30 
min, washing and 5 min pulse at 37°C. Confocal maximal intensity projections were 
analyzed with a custom made MatlabTM script, in which the cell outline was manually 
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segmented using boosted DAPI channel. The number of virus particles per cell was 
counted within the cell outlines and analyzed using Graphpad Prism, and Mann-
Whitney test for statistics. 
 
Statistical analyses 
Results for infection assays are shown as means from 3 parallel wells, unless 
otherwise indicated and experiments were repeated 3 to 4 times.  
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RESULTS 
 
Inhibition of GBF-1 enhances post entry steps in HAdV infection 
In search for host factors enhancing bystander effects and cell killing upon viral 
infection, we conducted an RNA-interference screen against guanine-nucleotide 
exchange factors (GEFs) of small GTPases implicated in secretion. The knock-down 
of GBF-1 stimulated adenovirus infection, measured with HAdV-C5 wild type (wt), 
replication-defective HAdV-C5-dE1_GFP and replication-competent HAdV-C2-
dE3B_GFP (Fig. 1 A). In both HAdV-C5-dE1_GFP and HAdV-C2-dE3B_GFP, GFP 
was under the major early cytomegalovirus (CMV) promoter. The extent of infection 
boost was between threefold and tenfold in different independent experiments and 
the boost with different GBF-1 siRNAs correlated with GBF-1 knockdown (Fig. 1 B-
D).  
We next employed a specific inhibitor of GBF-1, Golgicide A (GCA). GCA stabilizes 
GBF-1 on ER-Golgi membranes and interferes with ER-Golgi and intra-Golgi 
transport, and disperses the Golgi (54). Twenty µM GCA dispersed Golgi in A549 
cells, but had no strong effects on metabolic cell activity, shown by immunostaining 
of giantin and resazurin measurements, respectively (Fig. 2 A, B). GCA treatment of 
A549 cells for at least 5 h prior to infection enhanced infection with replicating and 
non-replicating HAdV-B and C, as measured by GFP transgene expression, but did 
not affect CMV-promoter driven GFP expression from transfected plasmid DNA (Fig. 
2 C, D, E). This suggested that the enhancement was not merely due to a promoter 
effect. The enhancement was also not due to increased virus association with cells, 
since quantification of atto565-labeled HAdV-C5 virus on A549 cells after 30 min 
virus binding at cold and 5min warm-up at 37°C indicated a less efficient virus 
binding to GCA-treated cells than to control cells (Fig. 2 F). If GCA was added 
shortly before or after virus, essentially no boosting effect was observed, strongly 
suggesting that GBF-1 is not acutely involved in infection, but rather through a 
mechanism that takes hours to build up (Fig 2 G). In further experiments we used a 
5 h GCA pretreatment to induce the infection enhancing effect.  
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Fig. 3 shows the effect of GCA on HAdV-C viral gene expression and progeny 
formation. E1A, the first viral gene expressed after delivery of the HAdV genome 
into the nucleus, produces five different mRNAs through differential splicing. The 
abundance of these transcripts is temporally regulated with the largest two 
transcripts (13S and 12S) dominating early in infection, and the smallest (9S) being 
more abundant late in infection after viral DNA replication (see for example, 32, 45). 
Furthermore, both positive and negative feedback mechanisms control the 
expression of E1A (73), and thus the E1A protein levels in infected cells become 
stabilized after initial increase. GCA enhanced the expression of HAdV-C5 13S and 
12S protein products at 5 h pi, and accelerated appearance of the 9S product at 5 
and 9 h pi (Fig. 3 A). In contrast, E1A levels in 293T cells, which harbor an 
integrated copy of the E1A region (15, 38) were not enhanced but rather reduced by 
GCA, yet GCA boosted HAdV-C5-dE1_GFP infection in these cells, albeit less 
efficiently than in A549 cells (Fig. 3 B, C). Further, GCA boosted the expression of 
the late viral protein VI in HAdV-C5 infected A549 cells by about 30% at 18 h pi 
compared to untreated cells (Fig. 3 D). GCA treatment resulted in enhanced viral 
titers 40 h pi both within cells and the extracellular medium (Fig. 3 E). Together, the 
data indicate that GCA enhances early and late viral gene products from 
extrachromosomal DNA in context of viral infection, rather than chromosomal DNA, 
and accelerates the formation of viral progeny.  
 
GCA enhances cancer cell killing 
We next tested whether inhibition of GBF-1 boosts HAdV infection of primary tumor 
stage III melanoma cultures M950822 and M980928, which are both CAR-positive 
(47, 55). GCA enhanced HAdV-C5-dE1_GFP infection several fold in both cases but 
had little effects in normal human WI38 fibroblasts (Fig. 4 A). GCA boosted the 
HAdV-C2-dE3B_GFP infection spread in M980928 cells measured by increase in 
number of infected cells at 48 h compared to 72 h pi in a live cell assay (Fig. 4 B). 
Crystal violet cell staining of HAdV-C5_wt infected M950822 and M980928 cells at 
72 h pi also indicated that virus cytotoxicity was enhanced by the GCA pretreatment 
(Fig. 4 C).  
To corroborate these results, we measured virus-induced changes to cell 
phenotypes by recording the impedance at the cell substrate interface using 
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xCELLigenceTM. Changes in impedance, also dubbed cell index (CI) can be 
measured in real time and label-free, and are proportional to parameters like cell 
adhesion, proliferation, cell–cell interactions, and cytotoxicity (58, 59). CI dropped as 
a linear function of log (MOI) upon infection with HAdV-C5_wt, but independent of 
the initial number of cells on the substrate (Fig. 5 A). The replication-defective 
HAdV-C5_dE1_GFP had less effects on CI than HAdV-C5_wt, and GCA 
pretreatment reduced the CI of HAdV-C5_wt infected A549 cells but had essentially 
no effects on CI of uninfected cells (Fig. 5 B, C). The CI measurements were 
corroborated by differential interference contrast (DIC) microscopy showing intact 
monolayers of uninfected cells and progressively rounded cells upon infection with 
HAdV-C5_wt and GCA treatment (Fig. 5 D, E, F). Note that the increase in number 
of attached cells 0-40 h post-seeding correlated with an increase in CI values 
(compare red and blue lines in Fig. 5F). The numbers of attached cells leveled off 40 
h post seeding, but the CI values continued to rise up to 50 h post seeding. Both the 
number of attached cells and CI values remained relatively constant from 75 h 
onwards in the case of uninfected cells or cells infected with the non-replicating 
HAdV-C5-dE1_GFP. In the case of HAdV-C5_wt infection both the CI and the 
amount of attached cells decreased after 85 h. Taking the CI value at 50 h as 100%, 
a 50% reduction in the CI was reached at ~100 h.  
In good agreement, manual counting indicated an equal distribution of rounded-off 
and attached cells at ~125 h. The sensitivity of cell viability measurements depends 
on the slope of dip in CI profile, a measure for attached cells. A steep slope of the CI 
profiles compared to a gradual slope obtained by cell counting indicated a higher 
sensitivity of xCELLigence to measure cytopathic effects compared to microscopic 
inspection. Importantly, the CI values of HAdV-C5_wt infection were strongly 
reduced in GCA treated cancer cells, including M950822 and M980928 melanoma 
cells, but not in normal WI38 cells compared to control-infected cells, as indicated by 
negative ΔCIT50 values for A549 and melanoma cells in Fig. 5 G. Notably the ΔCIT50 
values correlated well with HAdV-C5-dE1_GFP infection phenotype (Fig. 5 G), and 
confirmed the strong acceleration of HAdV infection by GCA.  
Contrary to HAdV infection, GCA increased the CIT values from human rhinovirus 
(HRV) A1A infections indicating reduced cytopathic effects, in good correlation with 
infection reduction (Fig. 5 H, I, J). This result was in agreement with the notions that 
GCA blocks replication of HRV related enteroviruses by dissociating Arf1 and COP-I 
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from Golgi membranes (69), and that HRV-A1A requires lipid flux between the ER 
and Golgi for replication (51).  
 
IRE-1 and XBP-1 are required for GCA enhancement of HAdV infection 
UPR enhances the protein folding capacity in the ER upon stress conditions, such 
as physical, chemical or biological insults, developmental processes or cancer (6). 
ER stress activates three signaling arms of UPR, IRE-1/XBP-1, PKR-like ER kinase 
(PERK) and ATF-6 (37). This can lead to cell protection or cell death. The former is 
favored by the IRE-1 branch, and the latter by the ATF-6 and PERK arms (37). 
Since knockdown of GBF-1 has been shown to induce the ATF-6 arm of the UPR 
(11), we tested whether the UPR was linked to the GCA boost of HAdV infection. 
The knock-down of IRE-1alpha with a pool of four siRNAs had the strongest effect 
on blunting GCA enhancement, although ATF-6B knock-down reduced the boost as 
well (Fig. 6 A). We confirmed these results with a pool of 30 synthetic siRNAs (siP-
RNAs), which were reported to have no detectable off-target effects (26). The siP-
IRE-1 RNAs blocked infection boost and reduced the IRE-1 protein levels (Fig. 6 B). 
The treatment of cells with GCA triggered the IRE-1/XBP-1 branch of the UPR, 
similar to the ER stress activator thapsigargin, as indicated by the activation of 
cytoplasmic splicing of XBP-1 mRNA, and this splicing was inhibited by the IRE-1 
nuclease inhibitor 4µ8C (Fig. 6 C, 13). Similar to GCA, thapsigargin boosted HAdV-
C5-dE1_GFP infection, and 4µ8C blunted both the GCA and thapsigargin boosts 
(Fig. 6 D). For HAdV-C5-dE1_GFP, the GCA infection boost was strongly, but not 
completely reduced in XBP-1 knock-out mouse embryo fibroblasts (36), akin to 
XBP-1 siP-RNA treated A549 cells (Fig. 6 E, F), suggesting a major, though not 
exclusive role of XBP-1 in boosting infection.  
The involvement of the IRE-1/XBP-1 branch in the GCA infection boost was further 
tested by live cell assays measuring infection spreading, where ‘comets’ of infected 
cells are formed by replicating HAdV-C2-dE3B_GFP (72). Comets are the 
equivalent of plaques, but obtained in the absence of gelling medium. They consist 
of dozens of GFP-positive cells in an elongated arrangement due to convection flow 
of cell-free viruses from lytic infected cells. GCA enhanced the formation of comets 
in a time-dependent manner (Fig. 7 A, B). Importantly, siP-RNAs against IRE-1 or 
XBP-1 blunted the GCA enhancement of comet formation (Fig. 7 C, D). Notably, 
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these siP-RNAs reduced the number of comets also without GCA treatment, 
implying that IRE-1 and XBP-1 contribute to the replication of HAdV in the absence 
of exogenous UPR stimulation.  
 
 
DISCUSSION 
 
IRE-1 senses unfolded proteins in the ER lumen, and this activates the IRE-1 
cytosolic kinase and endonuclease functions, and leads to splicing of XBP-1 mRNA 
yielding a transcript, which encodes the active XBP-1 transcription factor (64). XBP-
1 alleviates ER stress. We show here that the inhibition of the Arf-activator GBF-1 
by GCA induced the IRE-1/XBP-1 branch of the UPR (summarized in a model 
presented in Fig. 8). Chemical induction of the UPR boosted HAdV-C5 or B3 
infections, specifically in cancer cells. This may have therapeutic relevance, since 
the CAR-tropic HAdV-C5 is used to treat metastatic tumors, and the CD46/DSG-2 
tropic HAdV-B3 late stage cancers with down-regulated CAR, for example prostate 
cancer (50). Importantly, UPR is readily inducible in aggressive tumor cells, and 
promotes survival, angiogenesis, autophagy, epithelial-mesenchymal transition 
(EMT) or adaptation to hypoxic conditions. While angiogenesis, EMT and hypoxia 
adaptation depend on the PERK branch, the XBP-1 branch supports some forms of 
breast cancer (9, 18, 52). We expect that cells with fast or strong induction of IRE-
1/XBP-1 will enhance HAdV infection particularly well, while cells with low or slow 
induction will show a lesser infection boost upon chemical UPR induction. But in 
both cases, cancer cells can be killed by HAdV.  
On a mechanistic level, our results demonstrate that knockdown or inhibition of 
GBF-1 by GCA enhanced early viral and transgene expressions from adenovirus, 
enhanced late gene expression and cytopathic effects, formation and release of 
progeny from infected cells and enhanced virus spreading to neighboring cells. This 
cascade of effects boosted cancer cell killing. It was to a large extent dependent on 
the ability of GCA to induce the IRE-1/XBP-1 branch of the UPR. Interestingly, the 
GCA effects were not limited to wild type HAdV, but occurred also with replication-
defective HAdV expressing a transgene under the major immediate early CMV 
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promoter. Like for HAdV-C5_wt, this enhancement required IRE-1/XBP-1 
suggesting that this UPR branch acts on the E1A and the CMV promoters. However, 
promoter mechanisms are not sufficient to induce the viral infection boost, since 
GCA did not enhance gene expression from transfected plasmid DNA or 
chromosomally integrated viral E1 DNA. Furthermore, our results also indicate that 
GCA did not enhance virus binding to cells. We speculate that viral insults to cell 
integrity during entry enhance infection together with elements of the IRE-1/XBP-1 
pathway. This combined action may enhance nuclear import of the viral genome, 
affect the structure or protein composition of the viral genome in the nucleus, or 
involve epigenetic regulatory machineries (2, 31, 56, 70). Since UPR induction 
enhanced both the GFP expression from HAdV-C5-dE1_GFP and E1A or GFP 
expression from a replicating HAdV-C, this suggests that some early event in virus 
life cycle is targeted. However, whether this as-yet-unidentified early effect also fully 
explains the accelerated spreading of virus infection or whether infection is 
accelerated / enhanced by more than one mechanism is at present unclear. 
Furthermore, the exact molecular mechanism(s) by which IRE-1/XBP-1 enhance the 
HAdV infections is still unclear. This could involve one or more cellular (or viral) 
genes induced by XBP-1. 
The approach outlined here allows for the identification of host pathways boosting 
infection with viral vectors in any cell type of interest. Specifically, the cell 
impedance measurements can score cytopathic effects of virus infections in real 
time, and label-free, and can identify both infection enhancing and inhibiting 
compounds in semi-high throughput format without the need of constructing specific 
reporter viruses. Boosters of viral infection are needed to enhance and tune the 
efficacy of oncolytic virotherapies. Potential signaling branches downstream of the 
IRE-1 UPR node triggered by the small chemical GCA to enhance cancer cell killing 
are discussed in Fig. 8. Oncolytic therapies kill cancer cells, lead to inflammation, 
and ideally present tumor-associated antigens to immune cells to mount immune 
responses against tumors (43, 44). Viral oncolysis also crucially depends on efficient 
intratumoral transmission of the oncolytic agents, and the ability of the virus to 
overcome innate immunity (28). Notably, the spreading of HAdV-C occurs by cell-
free viruses after lysis of infected cells. Yet, spreading and oncolysis are limited both 
in cell cultures and organisms (27, 72). Our data raise the possibility to chemically 
tune viral oncolysis by manipulating the UPR, and apply this for cancer treatment. 
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FIGURE LEGENDS 
Figure 1: Knockdown of GBF-1 enhances HAdV infections 
(A) RNA interference mini-screen against Arf-GEFs identifies GBF-1 knock-down as 
an enhancer of HAdV-C5-dE1_GFP, HAdV-C5_wt and HAdV-C2-dE3B_GFP 
infections. Cells were reverse transfected with pooled siRNAs (1 pmol/well) against 
cytohesin (CYTH)-1, CYTH-2, CYTH-3, Brefeldin A-inhibited guanine nucleotide-
exchange protein (BIG)-1, BIG2 or GBF-1 for 48 h, infected as indicated, fixed 18 h 
pi, and analyzed for infection. Results are expressed as log 10 ratio of infected cells 
(mean nuclear intensity of GFP) normalized to control cells transfected with 
nontargeting siRNA. 
(B, C, D) Knockdown of GBF-1 siRNA enhances HAdV-C5-dE1_GFP infection in 
A549 cells. Single or pooled GBF-1 siRNAs, along with control non-targeting (NT), 
Kif11 (Kinesin family member protein 11) siRNAs and GFP siRNAs were reverse 
transfected into A549 cells and cells were infected 48h post transfection. Eighteen 
hours post infection cells were fixed, stained with DAPI and analyzed for infection. 
(B) shows representative images. Scale bar is 100µm. (C) shows quantification of 
GFP signal in cells transfected with the indicated siRNAs. RU=relative units 
represent mean nuclear GFP signal from three parallel samples ± SDs. The cell 
toxicity of the siRNAs was measured with the cell number shown on secondary x-
axis.  
 
Figure 2: Prolonged inhibition of GBF-1 enhances HAdV infection in A549 
cells, but not virus binding to cells 
(A) Dispersal of Golgi upon treatment of A549 cells with GBF-1 inhibitor GCA for 30 
min. Cells were fixed and immunostained with antibodies directed against the Golgi-
associated protein giantin (green) and nuclei (blue) were stained with DAPI. 
Samples were imaged by confocal fluorescence microscopy. Images show 
maximum projections of confocal sections. Note that control DMSO-treated cells 
showed normal peri-nuclear Golgi staining. Five µM GCA had no effect, 10 µM 
caused incomplete disruption of Golgi, and 20 µM induced efficient disruption of 
Golgi in all cells. Scale bar 20 µm. 
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(B) Minor effect of GCA on metabolic activity of A549 cells. Cells were treated with 
GCA or control DMSO for 5 h, and the metabolic activity in cells was measured by 
resazurin fluorescence assay (RFU=relative fluorescence unit). 
(C) Five-hour pre-incubation with GCA is sufficient to enhance HAdV-C5-dE1_GFP 
infection of A549 cells. Cells were pre-incubated with GCA or DMSO for 5 h, 
inoculated with HAdV-C5-dE1_GFP and infection was carried out in presence or 
absence of GCA. Cells were fixed 18h pi and mean nuclear intensity of GFP was 
used to score infection efficiency (RU= relative units). A graphical representation of 
the experiment is shown on the left, experimental results with mean values from 
three parallel experiments +/- SD on the right. 
(D) Five-hour pre-incubation with GCA enhances HAdV-C5-dE1_GFP, HAdV-
C2_dE1_GFP and HAdV-B3-dE1_GFP infection in A549 cells. 
(E) GCA has no effect on a plasmid-mediated CMV promoter-driven GFP 
expression. A549 cells were transfected with pMAX-GFP plasmid, 24 h post 
transfection treated with GCA for 5h, and analyzed for GFP expression 5 or 21 h 
post drug removal. 
(F) Decrease in atto565-labelled HAdV-C5 attachment to A549 cells upon GCA 
treatment. Cells were treated with GCA for 12 or 0.5 h followed by inoculation with 
atto565-labelled HAdV-C5_wt at cold for 30 min, washing and 5 min pulse at 37°C. 
Number of virus particles in individual cells was determined from maximum intensity 
projections of confocal stacks using a custom made MatlabTM script. One dot 
represents one cell. Error bars represent the means ± SEMs and p-values were 
calculated using Mann-Whitney test for statistics.  
(G) Acute inhibition of GBF-1 upon virus addition does not enhance HAdV-C5-
dE1_GFP infection in A549 cells. GCA or DMSO was added to cells 30 min prior to 
virus or as indicated pi, and incubation was continued until 18 h pi, when cells were 
analyzed.  
 
Figure 3: Inhibition of GBF-1 by GCA enhances HAdV-C early and late gene 
expression, as well as virus production in A549 cells. 
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(A) Five-hour pre-incubation with GCA accelerates E1A expression from HAdV-C5 
wild type in A549 cells, as indicated by Western blotting of infected cell lysates. E1A 
forms encoded by the differentially spliced E1A transcripts are indicated. Lower 
panel shows the β-tubulin loading control. 
(B) GCA does not increase E1A levels in uninfected 293T cells, which express E1A 
from a chromosomal copy. Cell extracts were prepared after 5h incubation with 
DMSO or GCA, and E1A levels were determined by immunoblot using β-tubulin as a 
loading control. 
(C) GCA boosts HAdV-C5-dE1_GFP infection in 293T cells. Cells were pre-
incubated with GCA for 5 h, inoculated with virus and analyzed for GFP expression 
18 h pi. 
(D) GBF-1 inhibition enhances expression of the late protein VI in A549 cells. Cells 
were pre-incubated with GCA for 5h, infected with HAdV-C5-wt and analyzed for 
protein VI expression 18h pi. Left panel shows representative images (green protein 
VI signal and blue DAPI signal). Scale bar 100µm. Right-hand panel shows 
quantification of average nuclear protein VI signal (RU=relative units). 
(E) Inhibition of GBF-1 accelerates the production and release of HAdV-C2-
dE3B_GFP in A549 cells 40 h pi. Cells were pre-incubated with DMSO or GCA for 
5h, inoculated with the virus (MOI 0.008) and 40 h pi progeny particles were 
collected from cells and culture supernatants. Titers of the cell-associated and 
supernatant fractions were determined on HeLa-ATCC cells by counting GFP 
positive cells 18 h pi. 
 
Figure 4: GBF-1 inhibition enhances adenovirus infection of melanoma cells 
(A) Inhibition of GBF-1 by GCA enhances HAdV-C5-dE1_GFP infection of M950822 
and M980928 melanoma cells, but not normal human WI38 fibroblasts. Cells were 
pre-incubated with DMSO or GCA for 5h, inoculated with the virus and analyzed 18 
h pi. Shown are representative images and quantification of mean nuclear GFP 
signal (RU=relative units). 
(B) Inhibition of GBF-1 enhances HAdV-C2-dE3B_GFP spreading in melanoma-
derived M980928 cells. The cells were pre-incubated with DMSO or GCA for 5 h 
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and inoculated with the virus (MOI ~ 0.00016). The data is from a live experiment 
with recordings every 4 h – 5h. Shown is quantification of the number of GFP- 
positive cells at 48 h and 72 h pi.  
(C) Inhibition of GBF-1 enhances HAdV-C5_wt-induced killing of M950822 and 
M980928 cells. The cells were pre-incubated with DMSO or GCA for 5 h, inoculated 
with HAdV-C5_wt (MOI 1) and stained with crystal violet 72 h pi. Right-hand panel 
shows quantification of crystal violet staining, which is proportional to cell numbers. 
 
Figure 5: Inhibition of GBF-1 enhances HAdV-induced cytopathic effects, but 
blocks rhinovirus infection. 
(A) Cell index (CI) profiles from impedance measurements of A549 infected with 
HAdV-C5_wt indicate cytopathic effects. Impedance was recorded every 15 min 
using xCELLigenceTM.  Each point represents the average value from two replicates 
with SD. Time on x-axis indicates the time post cell seeding. Vertical lines show the 
time of infection and horizontal lines refer to 50% of the maximum CI of non-infected 
cells. Right-hand panel shows regression fit of ∆CIT50 values, where each point 
represents a single ∆CIT50 value. Note that the CI-profile of HAdV-C5_wt infection is 
MOI but not cell density dependent. 
(B) A549 cells infected with HAdV-C5_wt (red) or replication-deficient HAdV-C5-
dE1_GFP (blue) yield significantly different CI profiles. The profile of HAdV-C5-
dE1_GFP infected cells is similar to that of non-infected control cells (brown). 
(C) Five-hour pre-incubation with GCA enhanced HAdV-C5_wt induced cytotoxicity 
in A549 cells. Data points represent means from two samples per condition ±SD.  
(D) DIC images of control and GCA-treated (5 h pre-incubation) uninfected and 
HAdV-C5_wt-infected A549 cells 72 h pi. Scale bar 50 µm. 
(E, F) Comparison of CI values with cell appearance in DIC images. Panel E shows 
representative DIC images of A549 cells classified as rounded (1, green), attached 
(2, blue) or in an intermediate state (3, brown). Scale bar 50 µm. The upper image is 
unprocessed, whereas the lower image shows an example of images that were 
band-pass filtered and contrast enhanced using ImageJ. The latter images were 
used for cell classification. Panel F compares the CI profiles of uninfected, HAdV-
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C5-dE1_GFP (MOI 1) and HAdV-C5_wt (MOI 1) infected A549 cells with the 
number of rounded, attached and intermediate cells in DIC images of corresponding 
parallel samples. Red line indicates CI, green line the number of rounded cells, blue 
line the number of attached cells and brown line the number of intermediate cells.  
(G) Summary of GCA-mediated infection enhancement for HAdV-C5-dE1_GFP and 
∆CIT50 values (h) for HAdV-C5_wt. Negative values in the ΔCIT50 column indicate 
that GCA-treated cells reached 50% maximum CI of non-infected cells earlier than 
control DMSO-treated cells. 
(H) GCA inhibits HRV-A1A infection of HeLa-Ohio cells as indicated by anti-VP2 
immunostaining. Cells were infected with HRV-A1A (MOI 0.01) in the presence of 20 
µM GCA and analyzed for VP2 expression 7h pi. Representative images are shown 
on the left (VP2 green and DAPI blue) and quantification of cytoplasmic VP2 signal 
on the right-hand side. 
(I) CI profile of HeLa-Ohio cells infected with HRV-A1A at different MOIs. Values are 
the average of two replicates including SD. 
(J) The GBF-1 inhibitor GCA reduced HRV-A1A-induced CPE in HeLa-Ohio cells. 
Cells were infected with HRV-A1A (MOI 0.01) in the presence of 20 µM GCA. Data 
represent means ±SD from 2 samples per condition. 
 
Figure 6: GCA enhances adenovirus infection through IRE-1 and XBP-1 
(A) Effect of knockdown of ER stress sensors on GCA-mediated infection boost. 
A549 cells were reverse transfected with control non-targeting siRNAs (NT) or 
pooled siRNAs against ER stress sensors ATF-6A, ATF-6B, PERK, IRE-1alpha. 
Forty-three h post transfection cells were pre-incubated with DMSO or GCA for 5h 
(no addition=no pretreatment), inoculated with HAdV-C5-dE1_GFP and average 
nuclear GFP signal was analyzed 18 h pi. RU=relative units. 
(B) IRE-1 knockdown by siPool-RNAs (siP) reduces HAdV-C5-dE1_GFP infection 
boost in GCA-treated A549 cells. siP Neg= non-targeting control siPool-RNAs. 
Intracellular IRE-1 levels were determined by Western blotting using β-tubulin as a 
loading control. 
29 	  
(C) GBF-1 inhibition by GCA induces ER stress and activates IRE-1 nuclease and 
splicing of XBP-1 mRNA. A549 cells were treated with GCA or the ER stress 
activator thapsigargin (Tg) for 5h, and IRE-1 activation was analyzed by PstI 
digestion of XBP1 cDNA amplicons. Spliced XBP-1 cDNA amplicon lacks a PstI site 
(1S), whereas the unspliced one retains the site and is cleaved into two fragments 
(2U and 3U) upon PstI digestion. Uppermost band * is a spliced/unspliced XBP-1 
hybrid amplicon  (24). XBP-1 splicing was inhibited by the IRE-1 nuclease inhibitor 
4µ8C in GCA- and Tg-treated cells. GAPDH cDNA amplicons were used as a 
loading control. 
(D) GCA-induced HAdV-C5-dE1_GFP infection boost in A549 cells requires IRE-1 
endonuclease activation. Cells were pre-incubated with GCA or Tg for 5h with or 
without 4µ8C, inoculated with HAdV-C5-dE1_GFP and analyzed for GFP expression 
18h pi.  
(E) Reduced GCA infection boost in XBP-1-/- mouse embryo fibroblasts. XBP-1+/+ or 
XBP-1 -/- MEFs were pre-incubated with GCA, inoculated with HAdV-C5-dE1_GFP 
and analyzed for GFP expression 18 h pi. 
(F) XBP-1 knockdown by siPool-RNAs (siP) reduces HAdV-C5-dE1_GFP infection 
boost in GCA-treated A549 cells. Cells were reverse transfected with siP-RNAs 
against XBP-1 or non-targeting control siP Neg, 72 h post transfection pre-incubated 
with GCA or DMSO for 5h, inoculated with HAdV-C5-dE1_GFP, and analyzed for 
GFP expression 18 h pi. Knockdown levels of the unspliced XBP-1 protein (XBP-1u) 
were controlled by Western blotting using β-tubulin as a loading control. 
 
Figure 7: Inhibition of GBF-1 by GCA enhances spreading of virus infection 
via IRE-1 and XBP-1.  
(A, B) Confluent A549 cells were pre-incubated with GCA for 5h and infected with 
replication competent HAdV-C2-dE3B_GFP (MOI 0.00016), and spreading of 
infection was analyzed by time-lapse fluorescence microscopy. (A) Spreading of 
infection is manifested by the typical comet phenotypes of infected GFP-positive 
cells. One of these comets is pointed out by an arrowhead. Arrowhead highlights 
one of many comets which increase in size as infection proceeds. (B) Quantification 
of the number of comets. The data is from two parallel experiments. 
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 (C, D) A549 cells were reverse transfected with siPool negative control (siP Neg) 
RNAs or siPool RNAs against IRE-1 or XBP-1. Seventy-two h post transfection cells 
were pre-incubated with GCA or DMSO for 5h, inoculated with HAdV-C2-
dE3B_GFP (MOI 0.008) and spreading of infection was analyzed by time-lapse 
fluorescence microscopy. (C) shows images from the 72 h pi recordings, and (D) 
shows the quantification of comets at the same time point. Data in (D) is from two 
parallel experiments. 
 
Figure 8: Model for the UPR-induced HAdV infection boost by GCA. 
ER stress can be induced by abnormal ER-associated lipids, redox potential, 
glycosylation, or protein flux through the secretory pathway, or by the depletion of 
calcium ions, for example by the Ca2+ ATPase inhibitor thapsigargin (29). Cells 
sense ER stress by three major pathways, the activating transcription factor 6 (ATF-
6), the PKR-like ER kinase (PERK), and the inositol-requiring enzyme 1 (IRE-1) 
pathway. Here we show that the small compound Golgicide A (GCA), which blocks 
the guanine nucleotide exchange factor GBF-1 of Arf-GTPases implicated in ER-
Golgi transport, induces the IRE-1/X-box binding protein 1 (XBP-1) branch of the 
UPR (depicted by green arrows). GCA and in some cases the knock-down of GBF-1 
by siRNA enhances infection of cancer cells with both replicating and non-replicating 
human adenovirus (HAdV) of the C- and B-species. This requires the RNase activity 
of IRE-1, and leads to the splicing of the XBP-1 mRNA in the cytoplasm, yielding an 
mRNA, which encodes the active XBP-1 transcription factor (also dubbed XBP-1s). 
XBP-1 splicing can be blocked by the IRE-1 RNase inhibitor 4µ8C (13). XBP-1s may 
enhance the transcription of both host and viral genes, and thereby boost early and 
late viral gene expression, virus release from infected cells and viral spreading. 
Besides the XBP-1 branch, IRE-1 also signals through regulated IRE-1-dependent 
decay (RIDD) generating double-strand RNA (RNA*), and leading to activation of 
retinoic acid-inducible gene 1 (RIG-I), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFkB), and downstream cytokines and chemokines, which may 
boost HAdV infection (10, 17, 30, 39). A third output from IRE-1 signaling is the 
degradation of micro RNA 17 (miR17), an inhibitor of the apoptotic caspase 2 (68).  
If this pathway were triggered by GCA, it may enhance HAdV induced cell killing.  
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Annotations: Green arrows highlight the GCA pathway activating the IRE-1/XBP-1 
branch of the UPR, and leading to HAdV infection boost, as shown in this work. 
Green dotted arrow denotes possible activations downstream of GCA-induced UPR. 
Blue dotted arrows relate to work previously published, and depict two signaling 
branches downstream of IRE-1 that could contribute to the enhancement of HAdV 
infection or cancer cell killing.  
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